66852-00-4

Usage

Uses

Used in Sports Nutrition Supplements:
L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-, methyl ester is used as a key ingredient in sports nutrition supplements for its ability to enhance protein synthesis and promote muscle growth, thereby supporting athletes and fitness enthusiasts in achieving their performance and physique goals.
Used in Muscle-Building Products:
In the realm of muscle-building products, L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-, methyl ester is utilized to provide a boost to muscle development and recovery, making it an essential component for those seeking to increase muscle mass and strength.
Used in Pharmaceutical Research:
L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-, methyl ester is employed as a building block in the synthesis of peptide and protein-based drugs, contributing to the development of new therapeutic agents for various medical conditions.
Used in the Treatment of Muscle Wasting:
L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-, methyl ester is being investigated for its potential therapeutic applications in the treatment of muscle wasting conditions, where its ability to enhance protein synthesis could provide a beneficial effect in managing muscle deterioration.
Used in the Treatment of Neurodegenerative Diseases:
L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-, methyl ester is also being explored for its possible role in the treatment of neurodegenerative diseases, given its potential to support protein synthesis and muscle health, which could have implications for diseases affecting motor function and muscle integrity.

Upstream product

• 2666-93-5 (S)-Leu-OMe 
• 126028-11-3 BocTyrCam 
• 3978-80-1 Boc-Tyr-OH 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 60-18-4 L-tyrosine 
• 61-90-5 L-leucine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 71641-29-7 Boc-tyrosinyl-leucine 
• 80066-32-6 Boc-Gln-Leu-Tyr-Leu-OMe 
• 80066-33-7 Boc-Val-Gln-Leu-Tyr-Leu-OMe 
• 80066-38-2 Boc-Tyr-Val-Gln-Leu-Tyr-Leu-OMe 
• 80066-34-8 Boc-Val-Tyr-Val-Gln-Leu-Tyr-Leu-OMe 
• 80066-35-9 Boc-Val-Tyr-Val-Gln-Leu-Tyr-Leu-NH-NH₂ 
• 1575822-58-0 Boc-DOPA-Leu-OMe 
• 1447815-64-6 L-isoseryl-L-tyrosyl-L-leucine 
• 919769-26-9 Boc-nitroargininyl-tyrosinyl-leucyl-prolyl-threonine p-nitrophenyl ester 
• 919769-24-7 Boc-nitroargininyl-tyrosinyl-leucyl-prolyl-threonine methyl ester 
• 919769-22-5 tyrosinyl-leucyl-prolyl-threonine methyl ester 
• 919769-23-6 Boc-tyrosinyl-leucyl-prolyl-threonine methyl ester 
• 80066-31-5 Boc-Leu-Tyr-Leu-OMe 

Relevant academic research and scientific papers

ACYLATION OF TYROSINE UNITS IN PEPTIDE COMPOUNDS

The present invention refers to a process for the selective modification of tyrosine units in a peptide sequence, in particular, by incorporating acyl groups in the ortho position of the hydroxyl residue of its aromatic ring. Likewise, the invention also

Phosphotyrosine prodrugs: design, synthesis and anti-STAT3 activity of ISS-610 aryloxy triester phosphoramidate prodrugs

Unmasked phohate groups of phosphotyrosine-containing molecules carry two negative charges at physiological pH, which compromise their (passive) cellular uptake. Also, these phosphate groups are often cleaved off by phosphatases. Together, these ultimatel

Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors

Aminopeptidase N (APN/CD13) is one of the essential proteins for tumour invasion, angiogenesis and metastasis as it is over-expressed on the surface of different tumour cells. Based on our previous work that L-isoserine dipeptide derivatives were potent APN inhibitors, we designed and synthesized L-isoserine tripeptide derivatives as APN inhibitors. Among these compounds, one compound 16l (IC50=2.51±0.2 M) showed similar inhibitory effect compared with control compound Bestatin (IC50=6.25±0.4 M) and it could be used as novel lead compound for the APN inhibitors development as anticancer agents in the future.

Helical pores self-assembled from homochiral dendritic dipeptides based on L-Tyr and nonpolar α-amino acids

The synthesis of dendritic dipeptides (4-3,4-3,5)12G2-CH 2-Boc-L-Tyr-X-OMe where X = Gly, L-Val, L-Leu, L-lle, L-Phe, and L-Pro is reported. Their self-assembly in bulk and in solution and the structural and retrostructural analysis of their pe

Synthetic and biological activity studies on a new cyclic pentapeptide, cyclonitroproctolin

The synthesis of a new biologically active cyclic pentapeptide, cyclonitroproctolin, cyclo(-Arg (NO2)-Tyr-Leu-Pro-Thr-) by solution phase synthesis is described. The structure of the synthetic peptide was characterized by IR, NMR, FAB mass and

ENZYMATIC PEPTIDE SYNTHESIS IN ORGANIC SOLVENT MEDIATED BY MODIFIED α-CHYMOTRYPSIN

Peptide couplings have been catalyzed in organic medium containing a slight amount of water (0.5percent) by PEG modified α-Chymotrypsin.